

## Bio

Marcus Hompesch, M.D.

Dr. Marcus Hompesch is an expert in the field of metabolic diseases, clinical metabolic research and the glucose clamp methodology, a licensed physician and entrepreneur.

Dr. Hompesch established Profil Institute for Clinical Research in San Diego, CA in 2004. Under Dr. Hompesch's leadership, Profil has become a leading institute providing services focused on the early phase clinical development of new diabetes and obesity treatments. Profil has been involved with almost every clinically promising drug and device development in diabetes in more than 140 clinical studies.

Dr. Hompesch received his M.D. from the University of Duesseldorf, Germany he spent eight years as a practicing physician receiving his training in internal medicine and diabetology at the Klinikum Wuppertal Medical Center, has actively been involved in designing, performing and publishing many clinical studies on metabolic diseases, in particular early phase diabetes studies. Based on their research Profil authors have published a substantial number of original research articles in peer reviewed medical journals.

Dr. Hompesch has also been a scientific associate at the department of Biostatistics and Medical Informatics at the Ruhr University in Bochum, Germany.

Between 2000 and 2003, prior to establishing the Profil Institute for Clinical Research in San Diego, Dr. Hompesch held various management roles, including executive positions at a contract research institute in Germany. Dr. Hompesch was also the founder of Med.IQ, a company that developed electronic patient records and disease management tools for patients with diabetes, which he led as CEO until completing the sale of the company in 2000.

## Positions and Honors

Since 1992, principal investigator for numerous clinical studies, many related to metabolic disorders and evaluating new drug therapies or new devices.

- 1996 – 1998 Scientific Associate, Department of Medical Informatics, Biometry and Epidemiology, Ruhr University, Bochum, Germany
- 1998 – 2000 Founder & CEO, MKD GmbH, Neuss, Germany; and Founder & President - CEO, med.iq AG, Neuss, Germany
- 2000 – 2001 Director Clinical Research, Profil Institute for Metabolic Research GmbH, Neuss, Germany
- 2000 – 2002 General Manager (CEO), Profil Outpatient Trials GmbH, Neuss, Germany
- 2000 – 2004 General Manager (CEO), Profil Obesity GmbH, Neuss, Germany
- 2001 – 2003 CFO, Profil Institute for Metabolic Research GmbH, Neuss, Germany
- 2003 – 2004 COO, Profil Institute for Metabolic Research GmbH, Neuss, Germany
- 2003 – 2004 Vice-President - COO, Profil Institute for Clinical Research, Inc., Chula Vista, CA, USA
- 2004 – pres President - CEO, Profil Institute for Clinical Research, Inc., Chula Vista, CA, USA

### Memberships:

American Diabetes Association, European Association for the Study of Diabetes, The Obesity Society, American Association for Pharmaceutical Physicians, American Association for Research Professionals, German Association for Pharmaceutical Medicine, American Association for Diabetes Educators.

### Selected publications

1. Freemantle, N., L. Blonde, et al. (2005). "Availability of inhaled insulin promotes greater perceived acceptance of insulin therapy in patients with type 2 diabetes." Diabetes Care **28**(2): 427-428.
2. Heinemann, L. and M. Hompesch (2008). "Role of physicians in the pharmaceutical industry and clinical research organizations: take more pride in your work." J Diabetes Sci Technol **2**(4): 707-709.
3. Hompesch, M., A. Kollmeier, et al. (2009). "Glycemic exposure is affected favorably by inhaled human insulin (Exubera) as compared with subcutaneous insulin glargine (Lantus) in patients with type 2 diabetes." Diabetes Technol Ther **11**(5): 307-313.
4. Hompesch, M., L. McManus, et al. (2008). "Intra-individual variability of the metabolic effect of a novel rapid-acting insulin (VIAject) in comparison to regular human insulin." J Diabetes Sci Technol **2**(4): 568-571.
5. Hompesch, M., S. M. Ocheltree, et al. (2009). "Pharmacokinetics and pharmacodynamics of insulin lispro protamine suspension compared with insulin glargine and insulin detemir in type 2 diabetes." Curr Med Res Opin **25**(11): 2679-2687.
6. Hompesch, M. and K. Rave (2008). "An analysis of how to measure glucose during glucose clamps: are glucose meters ready for research?" J Diabetes Sci Technol **2**(5): 896-898.
7. Hompesch, M., B. Troupin, et al. (2006). "Time-action profile of insulin detemir and NPH insulin in patients with type 2 diabetes from different ethnic groups." Diabetes Obes Metab **8**(5): 568-573.
8. Kapitza, C., M. Hompesch, et al. (2004). "Intrasubject variability of inhaled insulin in type 1 diabetes: a comparison with subcutaneous insulin." Diabetes Technol Ther **6**(4): 466-472.

9. Kempe, K., D. Price, et al. (2009). "Capillary and venous blood glucose concentrations measured during intravenous insulin and glucose infusion: a comparison of steady and dynamic states." Diabetes Technol Ther **11**(10): 669-674.
10. Kobberling, J. and M. Hompesch (1997). "alpha-Lipoic acid in NIDDM patients with cardiac autonomic neuropathy." Diabetes Care **20**(12): 1918-1920.
11. Nauck, M. A., M. Hompesch, et al. (2006). "Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes." Exp Clin Endocrinol Diabetes **114**(8): 417-423.
12. Ocheltree, S. M., M. Hompesch, et al. (2010). "Comparison of pharmacodynamic intrasubject variability of insulin lispro protamine suspension and insulin glargine in subjects with type 1 diabetes." Eur J Endocrinol **163**(2): 217-223.
13. Steiner, S., M. Hompesch, et al. (2008). "A novel insulin formulation with a more rapid onset of action." Diabetologia **51**(9): 1602-1606.